Equity Overview
Price & Market Data
Price: $0.36
Daily Change: +$0.025 / 6.95%
Range: $0.339 - $0.36
Market Cap: $8,300,746
Volume: 398,648
Performance Metrics
1 Week: 1.58%
1 Month: -1.81%
3 Months: -23.17%
6 Months: -54.23%
1 Year: -85.08%
YTD: -56.57%
Company Details
Employees: 4
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.